source
- Bristol Myers faces pivotal year as Q1 earnings season beginsThe weekly Endpoints newsletter for the last week of April highlighted that several pharmaceutical companies released their first-quarter earnings. Among them, Bristol Myers was singled out as bei…
- FDA approves Axsome Therapeutics' Auvelity for Alzheimer’s agitationThe U.S. Food and Drug Administration has granted approval to Axsome Therapeutics’ oral medication Auvelity for the treatment of agitation in patients with Alzheimer’s disease. Axsome noted that a…